Advertisement

Uncategorized

#left-column{width: 100% !important; padding-left: 0px !important;} #right-column{display: none !important;} #action-items{display: none !important;}

Advertisement

AstraZeneca will start a clinical trial to see if its cancer drug Calquence can suppress the excessive immune response COVID-19 triggers in some patients, the drugmaker said April 14.

March/April 2020 Issue of Becker’s Clinical Leadership & Infection Control ON THE COVER 2 patient experience strategies separating front-runners from the pack As a whole, the healthcare industry is making gains in patient experience. But that doesn’t mean health systems…

January/February 2020 Issue of Becker’s Clinical Leadership & Infection Control ON THE COVER 7 leaders on the patient safety issue they’d fix overnight Throughout 2019, Becker’s asked numerous clinical leaders the following question: “If you could fix one patient safety issue overnight,…

Advertisement